iCAD (NASDAQ:ICAD) Shares Cross Above 200-Day Moving Average – Here’s What Happened

iCAD, Inc. (NASDAQ:ICAD) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.57 and traded as high as $1.78. iCAD shares last traded at $1.78, with a volume of 282,089 shares trading hands.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of iCAD from a “sell” rating to a “hold” rating in a report on Thursday, November 21st.

iCAD Stock Performance

The business has a 50-day simple moving average of $1.81 and a two-hundred day simple moving average of $1.57. The company has a market capitalization of $47.24 million, a price-to-earnings ratio of -13.69 and a beta of 1.43.

Institutional Investors Weigh In On iCAD

An institutional investor recently raised its position in iCAD stock. Perritt Capital Management Inc raised its holdings in iCAD, Inc. (NASDAQ:ICAD) by 14.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 159,900 shares of the technology company’s stock after purchasing an additional 19,917 shares during the quarter. Perritt Capital Management Inc owned 0.60% of iCAD worth $208,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 24.61% of the company’s stock.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.